Want to join the conversation?
Generic pharma company $AKRX said it has launched Buprenorphine and Naloxone Sublingual Tablets CIII, used for treating opioid dependence, following an Oct. 15, 2015 FDA approval for the product. $AKRX also launched Tobramycin Injection USP multi-dose vials used for treating serious bacterial infections, following a Sept. 2014 approval.
Looking forward to the first $TSLA earnings after SolarCity acquisition.
What will be an ideal EPS range for $PZZA in its earnings today?